Nuclear Medicine/ Radiopharmaceuticals Market is Set to Boom by 2022
Nuclear Medicine/ Radiopharmaceuticals Market is expected to garner $8,207.5 million by 2022. The market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.
Nuclear Medicine/ Radiopharmaceuticals Market is expected to garner $8,207.5 million by 2022. The market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
Opportunity Analys<strong>is</strong> and Industry Forecast, 2016-2023<br />
Global<br />
Opportunity<br />
Analys<strong>is</strong> and<br />
Industry Forecast,<br />
2014-<strong>2022</strong>
Introductionof<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong> <strong>is</strong> expected <strong>to</strong> garner $8,207.5 million<br />
<strong>by</strong> <strong>2022</strong>.<br />
The global radiopharmaceuticals market <strong>is</strong> po<strong>is</strong>ed <strong>to</strong> grow at a significant pace, owing<br />
<strong>to</strong> growing demand for non-invasive techniques, availability of effective cancer<br />
treatment, and ability <strong>to</strong> observe the functioning of the organ from outside the body.<br />
Furthermore, increasing incidence of cancer & cardiovascular aliments, growing<br />
demand for alpha radio immunotherapy-based targeted cancer treatment, mounting<br />
call for nuclear imaging techniques, and advancements in radiotracers are expected <strong>to</strong><br />
open new avenues in the radiopharmaceuticals market.<br />
Fac<strong>to</strong>rs that are expected <strong>to</strong> drive the use of radiopharmaceuticals include changing<br />
lifestyle, elevated levels of stress, and ability <strong>to</strong> identify various d<strong>is</strong>eases sooner than<br />
other diagnostic tests. However, fac<strong>to</strong>rs such as supply volatility & log<strong>is</strong>tical challenges,<br />
stringent regula<strong>to</strong>ry vigil, and competition from conventional diagnostic procedures<br />
are anticipated <strong>to</strong> impede the market growth.
Introductionof<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
Scope of the Report<br />
Key Benefits<br />
Key Audiences
Key Benefits<br />
Therapeutics segment <strong>is</strong> projected <strong>to</strong> be the fastest growing segment in the<br />
radiopharmaceuticals market, reg<strong>is</strong>tering a CAGR of 16.9% from 2016 <strong>to</strong> <strong>2022</strong>.<br />
SPECT modality segment <strong>is</strong> expected <strong>to</strong> dominate the radiopharmaceuticals<br />
market in 2015 and expected <strong>to</strong> retain its position throughout the study period.<br />
Thyroid application segment <strong>is</strong> expected <strong>to</strong> exhibit double-digit CAGR of 11%.<br />
Oncology application segment <strong>is</strong> expected <strong>to</strong> continue <strong>to</strong> lead the<br />
radiopharmaceuticals market, accounting for close <strong>to</strong> 60% share <strong>by</strong> <strong>2022</strong>.<br />
Asia-Pacific <strong>is</strong> projected <strong>to</strong> be the fastest growing radiopharmaceuticals market,<br />
reg<strong>is</strong>tering a CAGR of 8.4%.
Table of Content (TOC)<br />
Chapter: 1 Introduction<br />
Chapter: 2 Executive Summary<br />
Chapter: 3 <strong>Market</strong> Overview<br />
Chapter: 4 World <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Type, 2014-<strong>2022</strong><br />
Chapter: 5 World <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Modality, 2014-<strong>2022</strong><br />
Chapter: 6 World <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Application, 2014-<strong>2022</strong><br />
Chapter: 7 World <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By End-user, 2014-<strong>2022</strong><br />
Chapter: 8 World <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2014-<strong>2022</strong><br />
Chapter: 9 Company Profiles
Segments<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
Type<br />
End-user<br />
Modality<br />
Segments<br />
Procedures<br />
Application
Segments<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
Diagnostic<br />
Type<br />
Therapeutic
Segments<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
SPECT<br />
Brachytherapy<br />
PET<br />
Modality<br />
Beta-emitters<br />
Alpha-emitters
Segments<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
Oncology<br />
Thyroid<br />
Application<br />
Cardiology<br />
Neurology
Company Profiles<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
1. Mallinckrodt plc.<br />
2. General Electric Co.<br />
3. Medtronic, plc. (Covidien, acquired <strong>by</strong> Medtronic)<br />
4. Bayer AG<br />
5. Cardinal Health, Inc.<br />
6. Lantheus Medical Imaging, Inc.
Thank You<br />
<strong>Nuclear</strong> <strong>Medicine</strong>/<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
ThankYou!<br />
For More Details<br />
Do Enquiry<br />
https://www.alliedmarketresearch.com/nuclear-medicine-radiopharmaceuticals-market<br />
Follow Us On
Change language